Cabot Wealth Management Inc. boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 5.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,026 shares of the medical device company’s stock after buying an additional 1,316 shares during the period. Cabot Wealth Management Inc.’s holdings in DexCom were worth $1,758,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Global X Management Co. LLC increased its stake in shares of DexCom by 33.1% in the second quarter. Global X Management Co. LLC now owns 30,516 shares of the medical device company’s stock worth $2,232,000 after buying an additional 7,588 shares during the last quarter. Pictet Asset Management Ltd. increased its stake in shares of DexCom by 36.5% in the second quarter. Pictet Asset Management Ltd. now owns 308,620 shares of the medical device company’s stock worth $20,628,000 after buying an additional 82,520 shares in the last quarter. Shaker Investments LLC OH increased its stake in shares of DexCom by 4.0% in the second quarter. Shaker Investments LLC OH now owns 40,055 shares of the medical device company’s stock worth $2,930,000 after buying an additional 1,545 shares in the last quarter. IFP Advisors Inc increased its stake in shares of DexCom by 30.5% in the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of DexCom by 19.2% in the second quarter. Sei Investments Co. now owns 581,670 shares of the medical device company’s stock worth $42,550,000 after buying an additional 93,498 shares in the last quarter.
Shares of DexCom, Inc. (DXCM) traded up 0.58% on Friday, hitting $73.20. 1,234,880 shares of the stock traded hands. The firm’s market cap is $6.34 billion. The firm has a 50 day moving average price of $70.65 and a 200 day moving average price of $74.91. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. During the same quarter in the prior year, the firm posted ($0.24) EPS. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. On average, equities analysts forecast that DexCom, Inc. will post ($0.77) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/cabot-wealth-management-inc-acquires-1316-shares-of-dexcom-inc-nasdaqdxcm-updated.html.
A number of equities research analysts recently weighed in on the stock. BidaskClub raised shares of DexCom from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. B. Riley reaffirmed a “buy” rating and issued a $95.00 target price on shares of DexCom in a research note on Sunday, May 7th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $90.00 target price (down from $105.00) on shares of DexCom in a research note on Wednesday, August 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 target price (down from $87.00) on shares of DexCom in a research note on Wednesday. Finally, Stephens reaffirmed an “overweight” rating and issued a $83.00 target price (down from $95.00) on shares of DexCom in a research note on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $87.00.
In related news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $69.07, for a total transaction of $414,420.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total value of $113,375.50. The disclosure for this sale can be found here. Insiders have sold a total of 33,726 shares of company stock worth $2,376,466 in the last 90 days. 1.70% of the stock is currently owned by insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.